share_log

LadRx (NASDAQ:CYTR) Earns Hold Rating From Analysts at StockNews.com

kopsource ·  Dec 27, 2022 02:02

StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research report released on Friday morning. The brokerage issued a hold rating on the stock.

LadRx Stock Up ∞

NASDAQ:CYTR opened at $0.09 on Friday. LadRx has a 1 year low of $0.05 and a 1 year high of $0.86. The business has a 50 day simple moving average of $0.10 and a 200-day simple moving average of $0.13.

Get LadRx alerts:

About LadRx

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

See Also

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • Three Healthcare Penny Stocks to Watch In The New Year
  • Southwest Airlines Stock, There is a Lot to Love
  • MarketBeat: Week in Review 12/19 – 12/23
  • These Steelmakers Deserve A Place On Your 2023 Watch List
  • Inflation Cools, Where Does The S&P 500 Go Now

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment